FoldRx Pharmaceuticals

Latest Headlines

Latest Headlines

Cystic Fibrosis group commits $58M for Pfizer research program

In another sign of the growing clout nonprofits have in the drug research field, the Cystic Fibrosis Foundation is stepping up with a $58 million commitment to back Pfizer's work on a new therapy aimed at the most common target of the lethal lung disease.

UPDATED: In rare slap, FDA review rips up Pfizer's case for tafamidis

After considering the trial's failure to meet its co-primary endpoints and questioning the data gathered at 8 sites, the agency is recommending that the experts gathering to discuss the drug's fate on Thursday reject the therapy.

Pfizer grabs leg up in pursuit of rare disease drug win

The FDA has given pharma giant Pfizer ($PFE) a fast-track review of its drug tafamidis meglumine for treating the rare disease known as transthyretin familial amyloid polyneuropathy, meaning the...

Pfizer, FoldRx drug extends survival

Data from a Phase II/III trial of transthyretin familial amyloid polyneuropathy (TTR-FAP) showed that Pfizer and FoldRx's drug tafamidis slowed disease progression over 30 months. No safety concerns

Pfizer buys FoldRx for rare disease division

With a new neurodegenerative disease therapy up for regulatory review and a fresh $29 million financing round sitting in the bank, FoldRx announced this morning that Pfizer has moved in to scoop up

FoldRx banks $29M for neurodegenerative drug application

Cambridge, MA-based FoldRx has rounded up $29 million in new funding, with new investors Novo Ventures and Morgenthaler Ventures joining Healthcare Ventures, Fidelity Biosciences, TPG Biotechnology,

FoldRx touts tafamidis data

FoldRx Pharmaceuticals announced that the Phase II/III study for tafamidis demonstrates that the drug "significantly halts disease progression for patients with a disease called